ondansetron intravenous / Generic mfg. - LARVOL DELTA

Effect of ondansetron on QTc interval prolongation in healthy pediatric patients: a systematic review and meta-analysis. (PubMed, Rev Paul Pediatr) - "There was a statistically significant increase in QTc and Tp-e intervals following ondansetron administration in healthy pediatric patients. However, it is highly unlikely that these changes result in cardiac dysrhythmia, suggesting no relationship between low-dose ondansetron use and an increased risk of dysrhythmia in healthy pediatric patients."

Clinical • Journal • Retrospective data • Review • Pediatrics

Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Tonsillectomy (clinicaltrials.gov) - P=N/A | N=210 | Not yet recruiting | Sponsor: Tanta University

New trial

Efficacy of intravenous amisulpride and ondansetron in preventing post-operative nausea and vomiting in patients undergoing craniotomy for supratentorial tumour surgery: A randomised non-inferiority trial. (PubMed, Indian J Anaesth) - "Patients undergoing neurosurgical procedures are at a high risk of post-operative nausea and vomiting (PONV). No treatment-related adverse events were observed in the amisulpride group. A single intra-operative intravenous dose of amisulpride (5 mg) at the end of the surgery was found to be non-inferior to 4 mg intravenous ondansetron in reducing the incidence and severity of PONV in patients undergoing supratentorial craniotomy."

Head-to-Head • Journal • Anesthesia • Critical care • Oncology

QIPB in Inguinal Hernia (clinicaltrials.gov) - P=N/A | N=70 | Recruiting | Sponsor: Konya City Hospital | Trial completion date: Nov 2025 ➔ Jun 2026 | Trial primary completion date: Nov 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • Gastroenterology • Pain

NELCER: Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix (clinicaltrials.gov) - P3 | N=348 | Completed | Sponsor: Tata Memorial Hospital | Active, not recruiting ➔ Completed

Trial completion • Cervical Cancer • Oncology • Solid Tumor • Uterine Cancer

Safety and outcomes of home reintroduction, including baked forms, in egg and milk FPIES (AAAAI 2026) - "Of these, 25/28 (89%) were successful; of the 3 failures, there were 2 mild reactions, and 1 moderate reaction requiring IV Zofran...Conclusions Gradual home reintroduction of baked and non-baked forms of egg and milk might be a safe option for carefully pre-selected children with egg and milk-FPIES, with high success rates and mild failures, managed at home. Our results suggest a potential pathway to facilitate safe reintroduction and reduction of unnecessary delays due to limited availability of FPIES-OFC."

Clinical • Food Hypersensitivity • Gastrointestinal Disorder • Immunology

Coronary Vasospasm Secondary to Ondansetron Use a Case Report and Review of the Literature (ISHLT 2026) - "On day 13, after receiving three doses of metoclopramide (10 mg) and one dose of intravenous ondansetron (4 mg) for nausea, he developed acute retrosternal chest pain with lateral ST-segment elevation and bigeminy. Clinicians should recognize this potential adverse effect, particularly in elderly patients, and avoid repeat exposure. Further pharmacovigilance studies are warranted to clarify mechanisms linking 5-HT₃ blockade and coronary hyperreactivity."

Case report • Clinical • Review • Cardiovascular • Colorectal Adenocarcinoma • Colorectal Cancer • Gastroenterology • Heart Failure • Hypotension • Rectal Adenocarcinoma • Solid Tumor

The effect of ondansetron intravenous administration to caloric intake for patients of gynecological surgery. (PubMed, J Pharm Health Care Sci) - "Our study indicated that ondansetron administration during gynecological surgery may have a positive effect on increasing postoperative caloric intake one day after surgery."

Journal • Anesthesia • Gynecology

The Pharmacokinetics of Intravenous and Subcutaneous Ondansetron in Female Beagle Dogs. (PubMed, J Vet Pharmacol Ther) - "Ondansetron administered SC at 0.5 mg/kg to adult healthy dogs has a similar bioavailability and a longer duration of action compared to the IV route of administration. Future pharmacokinetic and pharmacodynamic clinical studies should be performed in dogs utilizing the SC route of administration of ondansetron."

Journal • PK/PD data

Intravenous Versus Perineural Ondansetron for Laparoscopic Sleeve Gastrectomy (clinicaltrials.gov) - P=N/A | N=170 | Recruiting | Sponsor: Tanta University | Trial completion date: Mar 2026 ➔ Dec 2026 | Trial primary completion date: Mar 2026 ➔ Dec 2026

Head-to-Head • Trial completion date • Trial primary completion date • Gastrointestinal Disorder

Clinical characteristics of cyclic vomiting syndrome and the therapeutic efficacy of chlorpromazine combined with promethazine (PubMed, Zhonghua Er Ke Za Zhi) - "In contrast, 20 children who received intravenous drip ondansetron or omeprazole had a vomiting duration of 3 (3, 5) d. The vomiting duration in the chlorpromazine plus promethazine group was significantly shorter than that in the ondansetron or omeprazole group (Z=6.69, P<0.01). Vomiting is frequently accompanied by other gastrointestinal or autonomic symptoms. For acute episodes, chlorpromazine combined with promethazine is an effective and safe treatment."

Journal • Anorexia • CNS Disorders • Infectious Disease • Pain • Pediatrics • Psychiatry • Rare Diseases

Prospective Clinical Study on the Use of Fumaric Acid Tigelidine for the Prevention of Nausea and Vomiting Following Gynecological Laparoscopic Surgery (ChiCTR) - P=N/A | N=118 | Not yet recruiting | Sponsor: Henan Univ,Huaihe Hosp; Henan Univ,Huaihe Hosp

New trial

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (clinicaltrials.gov) - P2 | N=62 | Active, not recruiting | Sponsor: Pediatric Brain Tumor Consortium | Trial completion date: Oct 2030 ➔ Sep 2027 | Trial primary completion date: Oct 2029 ➔ Mar 2026

Trial completion date • Trial primary completion date • Brain Cancer • Ependymoma • Medulloblastoma • Oncology • Pediatrics • Solid Tumor • CD276

NELCER: Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix (clinicaltrials.gov) - P3 | N=348 | Active, not recruiting | Sponsor: Tata Memorial Hospital | Trial completion date: Jan 2026 ➔ Apr 2026

Trial completion date • Cervical Cancer • Oncology • Solid Tumor • Uterine Cancer

A study on the efficacy of aprepitant injection (submicron emulsion) in preventing postoperative nausea and vomiting in patients undergoing breast cancer surgery (ChiCTR) - P4 | N=300 | Completed | Sponsor: Shanxi Provincial Cancer Hospital; Shanxi Provincial Cancer Hospital

New P4 trial • Breast Cancer • Oncology • Solid Tumor

Intramuscular Promethazine Added to IV Ondansetron for the Prevention of Intrathecal Morphine-Induced Pruritus and Nausea After Cesarean Delivery: A Randomized Controlled Trial. (PubMed, Cureus) - "No differences were observed between patients receiving prophylactic IMP and those receiving saline placebo regarding pruritus, nausea, vomiting, agitation, fatigue, or pain at any time point. The addition of prophylactic IMP to standard care with prophylactic IV ondansetron did not reduce the incidence of intrathecal morphine-induced side effects after scheduled CD."

Journal • Anesthesia • Dermatology • Fatigue • Obstetrics • Pain • Pruritus

Effect of Ondansetron on Patient Tolerance, Efficacy and Endoscopist Workload in Unsedated Endoscopy for Upper Gastrointestinal Bleeding (clinicaltrials.gov) - P4 | N=80 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital

New P4 trial • Gastroenterology

Comparison of Intravenous Ondansetron and Low Dose Ketamine in Preventing Post Spinal Shivering (clinicaltrials.gov) - P=N/A | N=180 | Completed | Sponsor: Mayo Hospital Lahore

New trial

Efficacy of Enhanced Recovery After Surgery (ERAS) protocol in patients of small intestinal stoma closure (ANZCTR) - P=N/A | N=120 | Not yet recruiting | Sponsor: Mayo Hospital, Lahore

New trial

NELCER: Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix (clinicaltrials.gov) - P3 | N=348 | Active, not recruiting | Sponsor: Tata Memorial Hospital | Trial completion date: Sep 2025 ➔ Jan 2026

Trial completion date • Cervical Cancer • Oncology • Solid Tumor • Uterine Cancer

Extraskeletal Ewing Sarcoma Mimicking Benign Soft Tissue Tumors: A Rare Case. (PubMed, Cureus) - "Following multidisciplinary discussion, the patient was initiated on adjuvant chemotherapy using the CAV-IE (cyclophosphamide, doxorubicin, vincristine alternating with ifosfamide and etoposide), with a plan to complete 12 cycles, while radiotherapy was not indicated. She commenced her treatment with Cycle 1 of the IE component, accompanied by supportive care including intravenous fluids, ondansetron, omeprazole, and dexamethasone...She developed dysuria during hospitalization, and the treatment plan was adjusted to include an increased dose of mesna to enhance uroprotection. This case highlights the importance of considering EES in the differential diagnosis of persistent soft tissue masses, even in slow-growing lesions. It underscores the pivotal role of immunohistochemistry and multidisciplinary management in achieving a definitive diagnosis and favorable outcomes."

Journal • Ewing Sarcoma • Oncology • Sarcoma • Solid Tumor • BCL2 • CCND1 • CD99 • KIT • VIM

Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (clinicaltrials.gov) - P3 | N=388 | Recruiting | Sponsor: Jiuda Zhao | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Oncology • Solid Tumor

Intravenous Ondansetron versus Palonosetron for Prevention of Delayed Chemotherapy Induced Nausea and Vomiting for Moderately Emetogenic Chemotherapy Regimens (ASHP 2025) - No abstract available

CINV • Chemotherapy-Induced Nausea and Vomiting

Extended aprepitant in control of delayed emesis during induction chemotherapy for acute myeloid leukaemia – an multicentric, investigator-initiated, open label randomized controlled trial (ASH 2025) - "Introduction The management of chemotherapy induced nausea and vomiting (CINV) during intensive inductionchemotherapy for acute myeloid leukaemia (AML) is often not optimal due to prolonged infusion ofchemotherapy over 7 days as well as omission of steroids as an anti-emetic due to concern of infections.Addition of single 3-day course of oral aprepitant with ondansetron has shown to improve vomitingcontrol in acute phase (AP), but not in delayed phase (DP) for children with AML...All patients receivedintravenous/oral ondansetron 8mg thrice daily for 10 days with first dose starting half an hour beforeinitiation of chemotherapy on day 1...Patients received a planned chemotherapy regimen ofdaunorubicin 60mg/m2 days 1-3 and continuous infusion of cytarabine 100mg/m2/day for 7 days.Targeted therapies were added along with chemotherapy or chemotherapy were interrupted ordiscontinued based on prevailing clinical scenario as per discretion of local investigator...Adverse effect..."

Clinical • Acute Myelogenous Leukemia • Chemotherapy-Induced Nausea and Vomiting • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients (clinicaltrials.gov) - P3 | N=143 | Completed | Sponsor: Sichuan Cancer Hospital and Research Institute | Phase classification: P4 ➔ P3

Phase classification • Cervical Cancer • Chemotherapy-Induced Nausea and Vomiting • Endometrial Cancer • Fallopian Tube Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor